CANCER CENTER SUPPORT GRANT

这是一份申请为期五年的竞争续订多年的申请书 21-26目前由NCI指定的梅奥综合癌症中心。 在过去的四年里，梅奥基金会进行了一项重大投资 在癌症研究中建设新的实验室空间，招募 超过25名基础科学家。和创造九大基础科学 可供研究所所有调查人员使用的核心。扩张 在基础科学方面带动了四大新基础科学的发展 癌症中心的项目：癌症遗传学、生长因子、细胞 信号传递和基因调控。这些计划包括25个 调查人员以前-参加过前《免疫学》和 《生物化学与分子生物学》课程及30个新课程 调查人员。临床试验与抗癌药理学研究进展 由于增加了新的人员，也得到了加强。在 当前应用程序，请求支持九个内核：1)admini- 2)统计和临床研究支持系统，3) 药学，4)病理学，5)细胞免疫学，6)药理学，7) 细胞遗传学、分子探针、多肽合成和 测序。多肽合成和测序核心是新的。一个 病理学课程增加了组织准备能力。 核心(以前称为“组织分布”)。增加的发展资金 要求支持基础广泛的癌症控制和发展 预防计划，放射肿瘤学的发展计划，一个州- 最先进的共聚焦显微镜/亚细胞操作核心，以及 流行病学核心，支持未来的控制计划和新的 癌症遗传学项目。第一年申请的总直接成本为 186万美元。

This is an application for a five-year competitive renewal for years 21-26 of the present NCI-Designated Mayo Comprehensive Cancer Center. Over the past four years, the Mayo Foundation has made a major investment in cancer research with construction of new laboratory space, recruitment of more than 25 basic scientists. and the creation of 9 basic science cores available to all investigators at the Institution. The expansion in basic science has led to the development of four new basic science programs in the Cancer Center: Cancer Genetics, Growth Factors, Cell Signalling, and Gene Regulation. These programs include the 25 investigators previously-participating in the former "Immunology" and "Biochemistry and Molecular Biology" programs as well as 30 new investigators. The programs in Clinical Trials and Cancer Pharmacology have also been strengthened by the addition of new personnel. In the current application, support is requested for nine cores: 1) Admini- stration, 2) Statistical and Clinical Research Support Systems, 3) Pharmacy, 4) Pathology, 5) Cellular Immunology , 6) Pharmacology, 7) Cytogenetics, 8) Molecular Probes, and 9) Peptide Synthesis and Sequencing. The Peptide Synthesis and Sequencing core is new. A capability for histologic preparation has been added to the Pathology Core (formerly "Tissue Distribution"). Increased developmental funds are requested to support a broadly based developing cancer control and prevention program, a developing program in radiation oncology, a state- of-the-art confocal microscopy/subcellular manipulation core, and an epidemiology core to support future programs in control and the new program in cancer genetics. Total direct costs requested in year 1 are $1.86 million.